glp-1 receptor agonist medicines The New GLP-1 receptor agonists – How
Description
Are lifestyle therapies effective for NAFLD treatment
doi: 10.1155/2021/3361309 71 DaniilopoulouIVlachouELambrouGINtikoudiADokoutsidouEFasoiGet al
On injecting the glucagon into patients with insulinomas at the Institute of Neurology, Marks was astonished to see that they developed an early and profound hypoglycaemia
Trujillo, J.M., Nuffer, W., and Smith, B.A
The impact of NASH treatment on ASCVD is still unknown
One meta-analysis (April 2025) found no difference in incidence of aspiration (OR 1.04, 95% CI 0.871.25) despite the patients taking GLP-1 RAs having a higher incidence of residual gastric contents
